Showing 5861-5870 of 9116 results for "".
- Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasishttps://practicaldermatology.com/news/valeants-patient-access-and-pricing-committee-announces-pricing-for-siliq-as-lowest-priced-injectable-biologic-for-psoriasis/2458215/Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per month, which is the lowest injectable biologic psoriasis treatment cur
- RxPhoto Releases Updated HIPPA-Compliant Mobile Clinical Photography Apphttps://practicaldermatology.com/news/rxphoto-releases-updated-mobile-hippa-compliant-clinical-photo-app/2458213/RxPhoto has released version 3 of its mobile medical photography solution for medical practices and providers. Medical practices can now remain HIPAA compliant while using their mobile devices to securely capture, manage and share medical photos and videos.
- BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soonhttps://practicaldermatology.com/news/biopharmx-completes-phase-2b-trial-of-bpx-01-topline-results-coming-soon/2458217/BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now plans to announce topline data from the trial in the fi
- ThermiGen, an Almirall company, Names Vladimir Paul-Blanc President & General Managerhttps://practicaldermatology.com/news/thermigen-an-almirall-company-names-vladimir-paul-blanc-president-general-manager/2458219/Vladimir Paul-Blanc has been named President & General Manager of ThermiGen, LLC, starting May 1. He will report directly to the Executive Vice-president of Commercial Strategy of Almirall, Alfonso Ugarte, and he will be responsible for all general management responsibilities for the Thermi b
- EWG Surveys Personal Care Product Companies About Removing 1,4-Dioxanehttps://practicaldermatology.com/news/ewg-surveys-personal-care-product-companies-about-removing-14-dioxane/2458220/The Environmental Working Group (EWG) is surveying U.S. makers of personal care products to ask if they are working to remove 1,4-dioxane, a potential human carcinogen, from their products. At least 8,000 products on the market contain ethoxylated ingredie
- Novan: Positive Topline Results with Fungicidal SB208 in Phase 2 Trialhttps://practicaldermatology.com/news/nolan-positive-topline-results-with-fungicidal-sb208-in-phase-2-trial/2458222/Novan, Inc. has announced positive topline results from their Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. Novan’s SB208 Gel, at bo
- Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategyhttps://practicaldermatology.com/news/allergan-names-daphne-karydas-as-senior-vice-president-of-global-investor-relations-strategy/2458224/Daphne Karydas is Allergan’s new Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Ms. Karydas will lead the Company's engagement with the investment community, and will work with
- Business News: Allergan and ZELTIQ Announce Expiration of HSR Waiting Period for Pending Transactionhttps://practicaldermatology.com/news/business-news-allergan-and-zeltiq-announce-expiration-of-hsr-waiting-period-for-pending-transaction/2458225/Allergan is now one step closer to officially acquiring Zeltiq. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired with respect to Allergan's proposed acquisition of ZELTIQ.
- Phase 4 Studies of Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefithttps://practicaldermatology.com/news/phase-4-studies-of-restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit/2458226/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Merz Taps Bob Rhatigan as New President, CEOhttps://practicaldermatology.com/news/merz-taps-bob-rhatigan-as-new-president-ceo/2458229/Allergan vet Bob Rhatigan is the new President and Chief Executive Officer (CEO) of Merz North America, and Patrick Urban will serve as Chief Commercial Officer, effective immediately. In his new role, Mr. Rhatigan will assume responsibility for Merz&rsq